Carol A. French
University of Rochester
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carol A. French.
Journal of Clinical Oncology | 2012
Steven E. Lipshultz; David C. Landy; Gabriela Lopez-Mitnik; Stuart R. Lipsitz; Andrea S. Hinkle; Louis S. Constine; Carol A. French; Amy M. Rovitelli; Cindy Proukou; M. Jacob Adams; Tracie L. Miller
PURPOSE To determine whether cardiovascular abnormalities in childhood cancer survivors are restricted to patients exposed to cardiotoxic anthracyclines and cardiac irradiation and how risk factors for atherosclerotic disease and systemic inflammation contribute to global cardiovascular status. METHODS We assessed echocardiographic characteristics and atherosclerotic disease risk in 201 survivors of childhood cancer with and without exposure to cardiotoxic treatments at a median of 11 years after diagnosis (range, 3 to 32 years) and in 76 sibling controls. RESULTS The 156 exposed survivors had below normal left ventricular (LV) mass, wall thickness, contractility, and fractional shortening and above normal LV afterload. The 45 unexposed survivors also had below normal LV mass overall, and females had below normal LV wall thickness. Exposed and unexposed survivors, compared with siblings, had higher levels of N-terminal pro-brain natriuretic peptide (81.7 and 69.0 pg/mL, respectively, v 39.4 pg/mL), higher mean fasting serum levels of non-high-density lipoprotein cholesterol (126.5 and 121.1 mg/dL, respectively, v 109.8 mg/dL), higher insulin levels (10.4 and 10.5 μU/mL, respectively, v 8.2 μU/mL), and higher levels of high-sensitivity C-reactive protein (2.7 and 3.1 mg/L, respectively, v 0.9 mg/L; P < .001 for all comparisons). Age-adjusted, predicted-to-ideal 30-year risk of myocardial infarction, stroke, or coronary death was also higher for exposed and unexposed survivors compared with siblings (2.16 and 2.12, respectively, v 1.70; P < .01 for both comparisons). CONCLUSION Childhood cancer survivors not receiving cardiotoxic treatments nevertheless have cardiovascular abnormalities, systemic inflammation, and an increased risk of atherosclerotic disease. Survivorship guidelines should address cardiovascular concerns, including the risk of atherosclerotic disease and systemic inflammation, in exposed and unexposed survivors.
Cancer Epidemiology, Biomarkers & Prevention | 2010
Tracie L. Miller; Stuart R. Lipsitz; Gabriela Lopez-Mitnik; Andrea S. Hinkle; Louis S. Constine; M. Jacob Adams; Carol A. French; Cynthia Proukou; Amy M. Rovitelli; Steven E. Lipshultz
Background: Adiposity and the diseases associated with it, including cardiovascular disease, are emerging long-term complications of pediatric cancer survivors. Direct evaluations of adiposity and comparisons to contemporary controls that can differentiate recent trends in obesity from cancer-related treatments and sequelae are limited. Methods: We evaluated demographic, treatment, lifestyle, and endocrine factors at the time of dual-energy X-ray absorptiometry testing in 170 non-Hispanic white survivors and 71 sibling controls, and compared three measures of adiposity [body mass index (BMI), total body fat, and trunk fat]. For the survivors alone, we determined factors independently associated with BMI and body fat. Results: Survivors were at 12 years since diagnosis; 58% had leukemia or lymphoma. BMI did not differ between groups. Among males, body fat was greater in survivors than in controls (25.8% versus 20.7%; P = 0.007), as was trunk fat (26.7% versus 21.3%; P = 0.008). Total or trunk fat did not differ among females. Cholesterol, triglycerides, low-density lipoprotein cholesterol, and television viewing hours were higher among male survivors than in controls. Independent factors associated with higher BMI and total and trunk fat included any cranial radiation and television viewing hours, whereas prior treatment with cyclophosphamide was associated with lower BMI and body fat measures. Conclusions: Compared with siblings, male survivors have greater body fat and metabolic risks. Cranial irradiation and television hours are important risk factors for adiposity in pediatric cancer survivors. Impact: Pediatric cancer survivors should be carefully monitored for cardiovascular risk factors and sedentary lifestyles. Cancer Epidemiol Biomarkers Prev; 19(8); 2013–22. ©2010 AACR.
American Heart Journal | 2012
David C. Landy; Tracie L. Miller; Gabriela Lopez-Mitnik; Stuart R. Lipsitz; Andrea S. Hinkle; Louis S. Constine; Carol A. French; Amy M. Rovitelli; M. Jacob Adams; Steven E. Lipshultz
BACKGROUND Childhood cancer survivors are at increased risk of cardiovascular disease (CVD), which may be associated with traditional CVD risk factors. We used CVD risk aggregation instruments to describe survivor cardiometabolic health and compared their results with sibling controls. METHODS Traditional CVD risk factors measured in 110 survivors and 31 sibling controls between 15 and 39 years old were aggregated using Pathobiological Determinants of Atherosclerosis in Youth (PDAY) scores and the Framingham Risk Calculator (FRC) and expressed as ratios. The PDAY odds ratio represents the increased odds of currently having an advanced coronary artery lesion, and the FRC risk ratio represents the increased risk of having a myocardial infarction, stroke, or coronary death in the next 30 years. Ratios are relative to an individual of similar age and sex without CVD risk factors. RESULTS The median PDAY odds ratio for survivors was 2.2 (interquartile range 1.3-3.3), with 17% >4. The median FRC risk ratio was 1.7 (interquartile range 1.0-2.0), with 12% >4. Survivors and siblings had similar mean PDAY odds ratios (2.33 vs 2.29, P = .86) and FRC risk ratios (1.72 vs 1.53, P = .24). Cancer type and treatments were not associated with cardiometabolic health. There was a suggested association for physical inactivity with PDAY odds ratios (r = 0.17, P = .10) and FRC risk ratios (r = 0.19, P = .12). CONCLUSIONS Cardiometabolic health is poor in childhood cancer survivors but not different than that of their siblings, highlighting the importance of managing traditional CVD risk factors and considering novel exposures in survivors.
Pediatrics | 2004
Andrea S. Hinkle; Cindy Proukou; Carol A. French; Amy Kozlowski; Louis S. Constine; Stuart R. Lipsitz; Tracie L. Miller; Steve E. Lipshultz
Archive | 2003
Andrea S. Hinkle; Cindy Proukou; Sampada Deshpande; Sarah A. Duffy; Amy Kozlowski; Carol A. French; Steven E. Lipshultz
Clinica Chimica Acta | 1988
Robert A. Mooney; Bonnie L. McGorty; Carol A. French; Dean A. Arvan
Progress in Pediatric Cardiology | 2011
David C. Landy; Tracie L. Miller; Gabriela Lopez Mitnik; Stuart R. Lipsitz; Andrea S. Hinkle; Louis S. Constine; M. Jacob Adams; Carol A. French; Amy M. Rovitelli; Cindy Proukou; James D. Wilkinson; Steven E. Lipshultz
Journal of Clinical Oncology | 2010
Tracie L. Miller; David C. Landy; Gabriela Lopez-Mitnik; Stuart R. Lipsitz; Andrea S. Hinkle; Louis S. Constine; Carol A. French; Amy M. Rovitelli; M. J. Adams; Steven E. Lipshultz
Journal of Clinical Oncology | 2010
David C. Landy; Tracie L. Miller; Gabriela Lopez-Mitnik; Stuart R. Lipsitz; Andrea S. Hinkle; Louis S. Constine; Carol A. French; Amy M. Rovitelli; M. J. Adams; Steven E. Lipshultz
Journal of Clinical Oncology | 2005
Tracie L. Miller; Stuart R. Lipsitz; Carol A. French; Andrea S. Hinkle; Louis S. Constine; Amy Kozlowski; Cindy Proukou; Steven E. Lipshultz